公开(公告)号：US11566075B2

公开(公告)日：2023-01-31

申请号：US16085192

申请日：2017-03-14

Applicant: Cancer Research Technology Limited ,  The University of Birmingham

Inventor： Roy Bicknell ,  Steven Lee

IPC: C07K16/28 ,  G01N33/574 ,  A61K47/68 ,  A61P35/00 ,  A61K49/08 ,  A61K51/10 ,  A61K39/00

Abstract: The present invention relates to an isolated antibody, which selectively binds to CLEC14A, wherein said antibody (a) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises: (i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO. 105, preferably of SEQ ID NO: 2 or 42; (ii) a VH CDR2 that has the amino acid sequence of SEQ ID NO. 106, preferably of SEQ ID NO: 3 or 43; and/or (iii) a VH CDR3 that has the amino acid sequence of SEQ ID NO. 107, preferably of SEQ ID NO: 4 or 44; and/or wherein said light chain variable region comprises: (iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO. 108, preferably of SEQ ID NO: 6 or 46; (v) a VL CDR2 that has the amino acid sequence of SEQ ID NO. 109, preferably of SEQ ID NO: 7 or 47; and/or (vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO. 1 10, preferably of SEQ ID NO: 8 or 48; or (b) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises: (i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO: 22; (ii) a VH CDR2 that has the amino acid sequence of SEQ ID NO: 23; and/or (iii) a VH CDR3 that has the amino acid sequence of SEQ ID NO: 24; and/or wherein said light chain variable region comprises: (iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO: 26; (v) a VL CDR2 that has the amino acid sequence of SEQ ID NO: 27; and/or (vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO: 28; or (c) is an antibody which can compete with antibody (a) or (b) for binding to CLEC14A. The invention further provides chimeric antigen receptors, nucleic acid molecules encoding the antibodies of the invention or the chimeric antigen receptors, vectors, cells and methods/uses of the antibodies and chimeric antigen receptors.

公开(公告)号：US20180282418A1

公开(公告)日：2018-10-04

申请号：US15544323

申请日：2016-01-21

Applicant: Cancer Research Technology Limited

Inventor： Roy Bicknell ,  Peter Noy ,  Kabir Ali Khan

IPC: C07K16/28 ,  G01N33/50

Abstract: The invention provides a method of inhibiting angiogenes—is in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMNR2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule

公开(公告)号：US11919959B2

公开(公告)日：2024-03-05

申请号：US16992497

申请日：2020-08-13

Applicant: Cancer Research Technology Limited

Inventor： Roy Bicknell ,  Peter Noy ,  Kabir Ali Khan

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  G01N33/50 ,  A61K39/00

CPC classification number: C07K16/2851 ,  A01K67/0278 ,  A61P35/00 ,  C07K16/30 ,  G01N33/5008 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

公开(公告)号：US20210070867A1

公开(公告)日：2021-03-11

申请号：US16992497

申请日：2020-08-13

Applicant: Cancer Research Technology Limited

Inventor： Roy Bicknell ,  Peter Noy ,  Kabir Ali Khan

IPC: C07K16/28 ,  C07K16/30 ,  A01K67/027 ,  A61P35/00 ,  G01N33/50

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

公开(公告)号：US10808031B2

公开(公告)日：2020-10-20

申请号：US15544323

申请日：2016-01-21

Applicant: Cancer Research Technology Limited

Inventor： Roy Bicknell ,  Peter Noy ,  Kabir Ali Khan

IPC: C07K16/28 ,  C07K16/30 ,  A01K67/027 ,  A61P35/00 ,  G01N33/50 ,  A61K39/00

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.